Custom Search

News

Sunday 01 October 2006

Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.

By: Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, Alvarez-Larran A, Besses C.

Eur J Haematol 2006 Oct;77(4):338-40

We assessed the feasibility of a rapid infusion of rituximab with or without steroid-containing chemotherapy. Inclusion criteria: previous infusion of rituximab without grade 3 or 4 toxicity, lymphoid cells <5 x 10(9)/L and rituximab dose of 375 mg/m(2). Seventy patients were treated with a total of 319 rapid rituximab infusions [126 (40%) with and 193 (60%) without steroids]. Overall, rapid infusion of rituximab was well tolerated - there were no grade 3 or 4 adverse events. Only, three patients developed symptoms, all grade 1. In conclusion, rituximab administration in a 90-min infusion schedule is well tolerated and safe, both in patients who are administered steroids and in patients who are not.

Use of this site is subject to the following terms of use